Working paper
Evidence on orphan drugs
Report documents
-
Extract of the working paper
Evidence on orphan drugs
-
Working paper
Evidence on orphan drugs
Press releases
Orphan drugs: privilege of "fictitious" added benefit not justified
Drugs for rare diseases should also undergo a regular benefit assessment procedure at market entry. This is shown by a current IQWiG analysis.
Project details
- Project no.
- GA21-01
- Report type
- Working paper
- Status
- Commission completed
- Department/Division
- Drug Assessment